Articles tagged with Nephropathies
The Rutgers University Cell and DNA Repository has received two major NIH awards to support investigations into the genetics of mental disorders, metabolic diseases, and digestive health. The funds will enable researchers to study the genetic causes of complex diseases such as autism, bipolar disorder, and diabetes.
TheVisualMD.com offers interactive 3D visualizations of the cardiovascular system and various disease states. The platform provides a rich visual experience for professionals and patients to increase understanding and compliance.
A study found that hospitalized patients with chronic kidney disease (CKD) are at higher risk of experiencing adverse consequences of medical care. CKD patients were more likely to experience complications such as infections, respiratory failure, and post-operative hip fractures.
The American Society of Nephrology discusses the merits of using eGFR for early detection and treatment of CKD, highlighting concerns about misclassification and universal screening. Experts emphasize the need for education and proper use of eGFR to ensure accurate diagnosis and management.
A study found that high levels of alkaline phosphatase, a marker of bone disease, are associated with an increased risk of death in dialysis patients. Patients with elevated alkaline phosphatase levels were 25% more likely to die over a three-year period.
A study found that patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD) were less likely to use recommended medications after a heart attack, but 1-year adherence rates were similar for both groups. Rates of medication use varied significantly among different types of drugs.
Researchers found that consistently controlling parathyroid hormone, calcium, and phosphorous levels can prolong the lives of hemodialysis patients. Meeting multiple targets simultaneously was associated with improved survival rates, with a 51% higher risk of death for those who failed to meet any targets.
A cohort of half a million patients in Taiwan found that chronic kidney disease has a high prevalence and associated all-cause mortality, especially in low socioeconomic status groups. CKD is treatable and preventable at earlier stages, but awareness and treatment are often lacking globally.
A study by Drs. Seungho Ryu and Yoosoo Chang found that healthy individuals who gain weight, even up to a normal BMI, are at increased risk for developing chronic kidney disease. The U-shaped association between weight change and CKD development suggests that both significant weight loss and gain pose risks.
A study found that CKD patients have mild reductions in thyroid function, which may be a risk factor for cardiovascular disease and progressive kidney disease. The prevalence of subclinical hypothyroidism increased with declining kidney function.
A study found that non-alcoholic fatty liver disease (NAFLD) is linked to an increased risk of chronic kidney disease (CKD) in type 2 diabetes patients. NAFLD was associated with a 69% higher risk of CKD compared to those without the condition.
A study found that black patients with chronic kidney disease (CKD) have a higher risk of dying in the early stages of the disease compared to white patients. The disparities are attributed to sociological factors, including poverty and access-to-care, rather than biological differences.
Patients with systolic dysfunction are nearly twice as likely to die than those without the condition, according to a study analyzing 2,718 kidney transplant candidates. This increased mortality risk is similar to that seen in patients with cardiac ischemia.
A study found that activated vitamin D may reduce the risk of death by approximately one-fourth in patients with CKD, with a 20% reduction in the risk of either death or dialysis
Research by Johns Hopkins Medicine found that African-American patients with chronic kidney disease continue to lose kidney function despite strict blood pressure control. The study suggests that treating CKD in this population may require a more comprehensive approach, considering other factors beyond just blood pressure.
Researchers at UC San Diego School of Medicine found that low levels of adiponectin, a hormone produced by fat cells, are linked to elevated albumin protein in the urine and increased inflammation in the kidney. The study suggests that supplementing with adiponectin or other therapies may help protect kidney function in obese patients.
Researchers found that higher creatinine levels in black patients with kidney disease cannot be explained by differences in muscle mass. The study suggests new theories are needed to account for the racial difference, which could help explain why blacks are more affected by progressive chronic kidney disease.
A study published in the Journal of the American Society Nephrology found that raloxifene increases bone mineral density and reduces vertebral fractures in postmenopausal women with mild to moderate chronic kidney disease. The medication is safe and effective for this patient population, reversing bone loss and fracture risk.
A study found that elevated uric acid levels can precede significant changes in urine albumin levels, suggesting a potential early sign of diabetic kidney disease. Higher uric acid levels are associated with lower kidney function in patients with type 1 diabetes.
Two studies suggest that universal access to healthcare can reduce racial and ethnic barriers to treatment for kidney disease. Minority patients and those on Medicare or with less education had longer dialysis times before being wait-listed, highlighting the need for improved insurance coverage.
Researchers found that a protein called hypoxia-inducible-factor (HIF-1) promotes the synthesis of fibrous connective tissue in kidneys, leading to reduced oxygenation and progression of chronic kidney disease. The study used mice with silenced HIF-1a to demonstrate the link between low oxygen conditions and CKD.
Researchers predict a sharp increase in the US ESRD population by 2020, with over 785,000 patients expected to be affected. The study attributes this growth to the aging of Baby Boomers and rising diabetes rates.
Renal experts will discuss link between chronic kidney disease (CKD) and CVD, consequences of acute kidney injury, racial disparities in kidney disease outcomes, and treatment of anemia in kidney patients. The ASN's Public Policy News Briefing aims to improve health outcomes by highlighting significant research impacting public health.
Research suggests that frequent nocturnal hemodialysis can reduce the need for blood pressure medications and improve quality of life measures. However, it did not show benefits in anemia management. The study found reduced left ventricular hypertrophy and improved mineral metabolism.
A randomized controlled trial found that treating patients with chronic kidney disease with high doses of folic acid and B vitamins did not lower the rate of death or cardiovascular events. The study suggests that the underlying burden of disease may be too great to produce a measurable benefit from lowering homocysteine levels.
Recent progress in preventing and treating end-stage renal disease (ESRD) in the US is cause for cautious optimism, with improvements in survival expectations and increased use of fistulas for hemodialysis. However, skyrocketing costs are a major concern, with Medicare costs reaching $20.1 billion in 2004.
A study found that obesity is associated with higher levels of parathyroid hormone in patients with moderate to severe chronic kidney disease. Weight loss may help lower PTH levels, while other treatments could lead to weight loss. The association was strongest in patients with signs of malnutrition and inflammation.
Women with diabetes lose protective effect of estrogen on kidneys, which normally reduces risk of chronic kidney disease. Research suggests that hormone ratio rather than absolute levels determines impact on diabetic kidney disease.
Researchers have discovered that combining two blood pressure-lowering drugs with enzyme replacement therapy can slow the progression of kidney disease in patients with severe Fabry disease. The study found significant reductions in proteinuria and minimal decline in kidney function after an average of two and a half years' treatment.
A study reveals that hemoglobin levels vary among dialysis patients due to negative feedback control systems and individual sensitivity to ESA treatment. The analysis suggests optimizing treatment systems on a rational basis to reduce variation in hemoglobin values and stabilize dose regimens.
Researchers found that early treatment with ACE inhibitors can preserve kidney function and reduce the risk of irreversible damage in young patients with early-stage IgA nephropathy. The study suggests that starting treatment early may limit the need for renal replacement therapy.
Ms Bhavini Patel, Director of Pharmacy at Royal Darwin Hospital, has received a two-year Fellowship to address the evidence-practice gap in treating chronic kidney disease in Indigenous Australians. She aims to increase use of arteriovenous fistula for haemodialysis, reducing hospitalizations and complications.
The University of Virginia Health System has received a $583,000 NIH training grant to train four new researchers in kidney disease research annually. This multidisciplinary program aims to address the growing problem of kidney disease by equipping researchers with skills to translate lab research to clinical practice.
Chronic kidney disease affects a significant portion of the UK population, particularly elderly individuals taking multiple medications. Healthcare professionals require specific guidance on using drugs that can cause or be altered by kidney disease, as 'use with caution' advice is often insufficient.
Long-term Fosrenol treatment improves bone formation and reduces phosphorus levels in CKD stage 5 patients, according to a two-year study. The reformulated tablets also demonstrate efficacy as monotherapy for controlling serum phosphorus levels.
A Rutgers College of Nursing professor is testing a 12-week home-based exercise intervention program to improve physical functioning in older adults with CKD. The study aims to evaluate the feasibility of this program for a larger clinical trial and address the lack of targeted physical activity interventions for this population.
A new study published in Kidney International found that Fosrenol, a phosphate binder used to treat hyperphosphatemia in CKD Stage 5 patients, did not negatively impact cognitive function deterioration. The two-year trial compared Fosrenol with standard therapy and showed similar declines in cognitive function for both groups.
Patients with end-stage renal disease have a significantly shorter life expectancy after ICD implantation, highlighting the need for continued research on prevention and treatment strategies. The study calls into question the survival benefit of ICDs in patients with kidney disease who meet current implant indications.
A new kidney test, cystatin C, has been found to accurately predict higher risk of chronic kidney disease, cardiovascular disease, and death among elderly people. The study, published in Annals of Internal Medicine, suggests that a normal creatinine level should not reassure patients of normal kidney function.
A national study of 304 physicians reveals primary care doctors often fail to diagnose and refer patients with chronic kidney disease, a condition affecting an estimated 10 million Americans. The study suggests that early detection and referral can slow the progression of kidney disease in high-risk patients.
Researchers will follow over 540 children with mild to moderate kidney disease for four years, collecting blood, urine, and genetic samples. The study seeks to refine an existing method to measure glomerular filtration rate (GFR), a precise indicator of kidney function.
A study found that youth-onset type 2 diabetes is associated with a substantially increased risk of end-stage kidney disease and death between 25-55 years old. Participants with early-onset diabetes had a significantly higher incidence rate of kidney disease compared to those with older-onset diabetes.
A European-funded project aims to create a predictive diagnostic test for early detection of kidney loss and target effective therapies. Researchers will utilize nanobead technology and multiplexing platform to identify biomarkers in diabetic urine, enabling early identification of patients at risk.
Researchers at UVA Health System are investigating a novel approach to combat chronic kidney disease by targeting inflammation with adenosine drugs. Preliminary results show promising decreases in inflammation, urinary protein loss, and kidney scarring.
A review and meta-analysis of 127 trials found ACE inhibitors and ARBs no better than other drugs in preventing diabetic kidney disease. Treatment decisions for hypertension in renal disease should be based on blood-pressure-lowering effect, comparative tolerability, and cost.
Two studies on obesity pharmacotherapy were published in the New England Journal of Medicine, exploring the efficacy of lifestyle modification and pharmacological interventions. Dr. Susan Yanovski, director of the NIDDK's Obesity and Eating Disorders Program, is available to comment on these findings.
Researchers found a significant negative correlation between urine albumin levels and adiponectin hormone in obese mice. In humans, low adiponectin levels were associated with albuminuria, an indicator of kidney disease.
Researchers developed an animal model to study obstructive nephropathy, a common cause of end-stage renal disease (ESRD) in children. This model has helped identify potential targets for drug development, offering hope for improved treatment options for affected children.
The Australasian Kidney Trials Network will focus on new and innovative clinical research to provide better treatments and outcomes for patients. The network aims to address the growing health issue of chronic kidney disease affecting one in seven Australian adults.
A recent Mayo Clinic study found a significant association between benign prostate obstruction and chronic kidney disease in older men. BPH can cause bladder outlet obstruction, leading to increased risk of death, hospitalization, and cardiovascular events.
A recent study found that the APOE e2 allele is associated with a moderately increased risk for chronic kidney disease, whereas the e4 variant provides protection. The study involved 14,520 middle-aged participants and confirmed previous findings on the role of genetics in kidney disease.
A new kidney function test, cystatin-C, is more effective than the standard test creatinine in predicting death and cardiovascular outcomes in elderly participants. The study found that 60% of participants with high cystatin-C levels had abnormal kidney function, putting them at medium or high risk for cardiovascular complications.
The new guidelines provide a framework for identifying patients at risk of kidney disease, evaluating their kidney function, and implementing management strategies. Nearly one-third of HIV-infected patients have abnormal protein in the urine, a warning sign of potential kidney trouble.
Researchers at Yale University identified a novel human kidney protein called renalase that regulates both heart contraction and blood pressure. The protein is a strong candidate for easily administered treatment of advanced kidney and cardiovascular disease.
A new cancer drug, SAHA, has shown potential in reducing kidney disease in lupus patients by inhibiting the onset of lupus-related kidney disease and decreasing spleen size. Further studies are needed to confirm its effectiveness and understand its anti-inflammatory properties.
Researchers found hospitalizations drive cost increase before dialysis, emphasizing the importance of optimal chronic kidney disease management. Early diagnosis and intervention may prevent avoidable morbidity and reduce future healthcare expenses.
A new study shows that consuming isolated soy protein can slow down the progression of diabetic kidney disease and improve coronary heart disease in patients with type 2 diabetes. The study found a significant reduction in urinary albumin levels and an improvement in HDL cholesterol levels among participants who consumed soy protein.
Researchers at SLU School of Medicine discovered a new drug, Cinacalcet, that successfully treated hyperparathyroidism, a common side effect of kidney disease. The treatment works by fooling the parathyroid glands into thinking calcium levels are higher than they actually are.
A $3.3 million NIH grant-funded study will compare six-times-per-week overnight home hemodialysis to standard three-times-a-week hemodialysis at dialysis centers. The research aims to determine if the higher dose of dialysis improves patient outcomes, including hospitalization rates and quality of life.
A study found that cardiovascular disease risk factors, such as diabetes and hypertension, predict the development of new-onset kidney disease in unselected participants. Patients with mildly reduced GFR should be monitored for progression to kidney disease.